Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-19-022937
Filing Date
2019-11-12
Accepted
2019-11-12 16:32:38
Documents
42
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0919_actiniumpharma.htm 10-Q 586459
2 CERTIFICATION f10q0919ex31-1_actinium.htm EX-31.1 11774
3 CERTIFICATION f10q0919ex31-2_actinium.htm EX-31.2 11278
4 CERTIFICATION f10q0919ex32-1_actinium.htm EX-32.1 7107
5 CERTIFICATION f10q0919ex32-2_actinium.htm EX-32.2 6565
  Complete submission text file 0001213900-19-022937.txt   2492393

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE atnm-20190930.xml EX-101.INS 309232
7 XBRL SCHEMA FILE atnm-20190930.xsd EX-101.SCH 37934
8 XBRL CALCULATION FILE atnm-20190930_cal.xml EX-101.CAL 35511
9 XBRL DEFINITION FILE atnm-20190930_def.xml EX-101.DEF 114764
10 XBRL LABEL FILE atnm-20190930_lab.xml EX-101.LAB 275270
11 XBRL PRESENTATION FILE atnm-20190930_pre.xml EX-101.PRE 189663
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 191210042
SIC: 2834 Pharmaceutical Preparations